EMD Serono names VP, medical affairs
This article was originally published in Scrip
Rockland, Massachusetts-based EMD Serono, the US biopharmaceuticals subsidiary of Germany's Merck KGaA, has appointed Dr Frederick E Munschauer vice-president of medical affairs, neurology and immunology. In this capacity, Dr Munschauer will lead the medical affairs activities for clinical, commercial and business development projects and collaborations for Rebif (interferon beta-1a) as well as the company’s immunology and neurology pipeline. He joins EMD Serono from Biogen, where he was chief medical advisor.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.